Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 1/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28262838 | 0.86 | HPGD (0.50) | CYP17A1 | |
| SCHEMBL13604350 | 0.83 | MEN1 (0.63) | CYP11B1CYP11B2CYP19A1TBXAS1ADRA2C | |
| SCHEMBL4484577 | 0.81 | SIRT2 (0.48) | CYP17A1 | |
| SCHEMBL28537669 | 0.81 | SIRT2 (0.47) | CYP17A1 | |
| SCHEMBL28867909 | 0.81 | TSHR (0.70) | CYP17A1S1PR1 | |
| SCHEMBL25128954 | 0.80 | NPY1R (0.44) | CYP17A1 | |
| SCHEMBL4480475 | 0.79 | SIRT2 (0.46) | CYP17A1 | |
| SCHEMBL4476784 | 0.79 | BRD4 (0.51) | CYP17A1 | |
| SCHEMBL4480759 | 0.79 | JAK2 (0.49) | AGTR2CYP11B1CYP11B2CYP19A1TBXAS1 | |
| SCHEMBL13604563 | 0.79 | JAK2 (0.49) | AGTR2CYP11B1CYP11B2CYP19A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635697-B2 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635697-B2 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-20060211706-A1 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211706-A1 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | FNTB, FNTA, FDPS | AGTR2 3237/4885CYP11B1 320/4885CYP11B2 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.